PharmaEssentia announced on the 19th that the board of directors had decided to amend the agenda for the 113th Annual General Meeting of Shareholders. This year, the routine fundraising-related proposal will not be presented at the shareholders' meeting. The company stated that with the operational goal of "maximizing profits in the core business" for this year, considering the current ample funds and healthy financial situation, no routine fundraising-related proposals will be put forward.
PharmaEssentia pointed out that the management team prioritizes maximizing shareholder equity. With the operational goal of "maximizing profits in the core business" for this year, the expansion of business is still under careful evaluation and has not yet required substantial investment. Therefore, the company still possesses ample funds and a healthy financial condition. As a result, no routine fundraising-related proposals will be presented at this year's shareholders' meeting.
Furthermore, PharmaEssentia stated that sales of its new drug Ropeginterferon alfa-2b (Ropeg, also known as P1101), used in treating Polycythemia Vera (PV), continue to grow globally. Particularly, the American NCCN guidelines have listed Ropeg as the preferred medication for PV, regardless of the patient's risk level. Insurance companies prioritize coverage for it. The company's revenue for the first three months of this year reached NT$1.65 billion, with a year-on-year growth rate of 86.3%. The core business is progressing smoothly.
Resource (Mandarin):
